Complement Inhibitors Market Report 2026

The complement inhibitors market size has grown exponentially in recent years. It will grow from $21.26 billion in 2025 to $27.63 billion in 2026 at a compound annual growth rate (CAGR) of 30%. The growth in the historic period can be attributed to advances in complement biology, rising pnh and ahus diagnosis, biologics approval growth, expansion of specialty care, increased immunology research.

The complement inhibitors market size is expected to see exponential growth in the next few years. It will grow to $77.86 billion in 2030 at a compound annual growth rate (CAGR) of 29.6%. The growth in the forecast period can be attributed to growth in rare disease treatments, expanding complement research, rising personalized medicine adoption, increasing biologics funding, improved diagnostic capabilities. Major trends in the forecast period include rising use in rare immune-mediated disorders, increasing adoption of c5 inhibitors, growing focus on targeted immune regulation, expansion of biologic drug pipelines, increased long-term therapy utilization.

The increasing emphasis on personalized medicine is anticipated to drive the expansion of the complement inhibitors sector in the coming years. Personalized medicine focuses on customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. Its adoption is rising due to advancements in genomics, wider availability of biomarker-based diagnostics, enhanced data analytics technologies, and growing demand for more precise and effective therapies. Complement inhibitors operate in a similar manner to personalized medicine by targeting specific elements of the complement system according to a patient’s unique disease profile, genetic makeup, and complement activity levels. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Consequently, the rising focus on personalized medicine is fueling the growth of the complement inhibitors sector.

Major companies operating in the complement inhibitors sector are concentrating on developing monoclonal antibodies, such as C5-targeted complement inhibition therapies, to improve terminal complement regulation and provide sustained protection against haemolysis in patients with paroxysmal nocturnal haemoglobinuria (PNH). C5-targeted complement inhibition therapy is a treatment approach that specifically blocks the complement protein C5 to prevent its activation and subsequent cleavage into C5a and C5b. For example, in August 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, obtained approval from the European Commission for PiaSky (crovalimab) for adults and adolescents with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to or previously treated with C5 inhibitors. PiaSky (crovalimab) is a monoclonal antibody that targets complement protein C5 to stop its cleavage, thereby preventing the formation of the membrane attack complex (MAC). This inhibits terminal complement-mediated intravascular haemolysis. By reducing hemolysis, PiaSky helps improve hemoglobin levels, lowers the need for blood transfusions, and alleviates symptoms such as fatigue and anemia, enhancing patients’ quality of life.

In September 2023, Magenta Therapeutics Inc., a US-based clinical-stage biotechnology company, merged with Dianthus Therapeutics Inc. for an undisclosed sum. The merged entity will concentrate on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103, which is currently in a Phase I clinical trial. Dianthus Therapeutics Inc. is a US-based clinical-stage biotechnology company dedicated to developing next-generation antibody complement therapeutics for severe autoimmune diseases.

Major companies operating in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals.

North America was the largest region in the complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complement inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the complement inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised the cost of biologic manufacturing inputs, cell culture media, and cold chain logistics used in the production of C3 and C5 inhibitor therapies. The impact is most visible in advanced complement inhibitor segments, where process complexity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on global biologics supply chains. Rising tariff related expenses have influenced production economics, pricing strategies, and capacity planning. Tariffs have encouraged regional biologics manufacturing, expanded local production capabilities, and strengthened biopharmaceutical supply chains over the long term.

The complement inhibitors market research report is one of a series of new reports that provides complement inhibitors market statistics, including complement inhibitors industry global market size, regional shares, competitors with a complement inhibitors market share, detailed complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the complement inhibitors industry. This complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Complement inhibitors are therapeutic agents developed to modulate or block the activity of the complement system, a key part of the immune system involved in inflammation, pathogen clearance, and cell lysis. These inhibitors act on specific complement components, such as complement component 3 (C3) or complement component 5 (C5), to prevent excessive activation and protect tissues from damage in conditions like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).

The primary categories of products in the complement inhibitors sector include complement component 3 (C3) inhibitors, complement component 5 (C5) inhibitors, and complement factor D inhibitors. Complement Component 3 (C3) inhibitors are a group of therapeutic agents designed to prevent the activation of C3, a key protein in the complement cascade. The mechanisms of action for complement inhibitors encompass alternative pathway inhibitors, classical pathway inhibitors, and lectin pathway inhibitors. These treatments target various conditions such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (GMG), and paroxysmal nocturnal hemoglobinuria (PNH). They are delivered via intravenous (IV) and subcutaneous (SC) methods, accommodating a wide range of patient groups, including adults, geriatrics, and pediatrics.

The complement inhibitors market consists of sales of small molecule inhibitors, recombinant proteins and biologics designed to regulate the complement system and treat complement-mediated diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.